The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer.
Karen L. Reckamp
Consultant or Advisory Role - Genentech; Tragara Pharmaceuticals
Honoraria - Genentech
Research Funding - Astellas Pharma; Pfizer
Marianna Koczywas
No relevant relationships to disclose
Mihaela C. Cristea
No relevant relationships to disclose
Jonathan Dowell
Research Funding - Genentech
Brian Gardner
No relevant relationships to disclose
Ginger L Milne
No relevant relationships to disclose
Robert A. Figlin
No relevant relationships to disclose
Robert M. Elashoff
No relevant relationships to disclose
Steven M. Dubinett
Consultant or Advisory Role - Tragara Pharmaceuticals